We serve Chemical Name:Methandriol CAS:521-10-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Methandriol
CAS.NO:521-10-8
Synonyms:Megabion;MFCD00021126;Androdiol;EINECS 208-301-0;Neostene;Stenibel;Cenabolic;Masdiol;Hibol;Metandiol;Nabadial;Esjaydiol
Molecular Formula:C20H32O2
Molecular Weight:304.46700
HS Code:2937290019
Physical and Chemical Properties:
Melting point:205 °C
Boiling point:430.4ºC at 760mmHg
Density:1.11g/cm3
Index of Refraction:-75 ° (C=1, EtOH)
PSA:40.46000
Exact Mass:304.24000
LogP:4.06110
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:3249
Packing Group:III
Contact us for information like Megabion chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Esjaydiol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Esjaydiol Use and application,Androdiol technical grade,usp/ep/jp grade.
Related News: ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.�� Methandriol manufacturer The latest outbreak comes as China grapples with an African swine fever epidemic that has infected tens of thousands of pigs. It could stoke more worries among its people about the country��s food supply. Methandriol supplier The latest outbreak comes as China grapples with an African swine fever epidemic that has infected tens of thousands of pigs. It could stoke more worries among its people about the country��s food supply. Methandriol vendor This is very visible in herbal medicines in which the API is frequently a combination of several mixtures and/or substances which when used together cause pharmacological activity on the body. Methandriol factory ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.��
